Pacira BioSciences (PCRX) Change in Account Payables (2010 - 2026)

Pacira BioSciences' Change in Account Payables history runs 12 years deep, the most recent figure standing at -$936000.0 for Q1 2026.

• In Q1 2026, Change in Account Payables fell 137.99% year-over-year to -$936000.0; the TTM figure through Mar 2026 stood at -$9.0 million (down 171.85% YoY), while the FY2025 annual figure was -$5.6 million, down 281.52% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$936000.0, up from -$2.9 million in the prior quarter.
• The five-year high for Change in Account Payables was $9.7 million in Q2 2024, with the low at -$12.0 million in Q3 2025.
• The 5-year median for Change in Account Payables is -$325000.0 (2024), against an average of $219882.4.
• The sharpest annual moves came in 2023 and 2025: Change in Account Payables surged 932.94% in 2023, then slumped 1985.87% in 2025.
• Pacira BioSciences' Change in Account Payables stood at $1.6 million in 2022, then sank by 167.38% to -$1.1 million in 2023, then soared by 69.68% to -$325000.0 in 2024, then sank by 801.23% to -$2.9 million in 2025, then surged by 68.04% to -$936000.0 in 2026.
• Business Quant data shows PCRX's Change in Account Payables at -$936000.0 in Q1 2026, -$2.9 million in Q4 2025, and -$12.0 million in Q3 2025.